[Regenerative medicine: stem cells, cellular and matricial interactions in the reconstruction of skin and cornea by tissue engineering].
Considering that there is a shortage of organ donor, the aim of tissue engineering is to develop substitutes for the replacement of wounded or diseased tissues. Autologous tissue is evidently a preferable transplant material for long-term graft persistence because of the unavoidable rejection reaction occuring against allogeneic transplant. For the production of such substitutes, it is essential to control the culture conditions for post-natal human stem cells. Furthermore, histological organization and functionality of reconstructed tissues must approach those of native organs. For self-renewing tissues such as skin and cornea, tissue engineering strategies must include the preservation of stem cells during the in vitro process as well as after grafting to ensure the long-term regeneration of the transplants. We described a tissue engineering method named the self-assembly approach allowing the production of autologous living organs from human cells without any exogenous biomaterial. This approach is based on the capacity of mesenchymal cells to create in vitro their own extracellular matrix and then reform a tissue. Thereafter, various techniques allow the reorganization of such tissues in more complex organ such as valve leaflets, blood vessels, skin or cornea. These tissues offer the hope of new alternatives for organ transplantation in the future. In this review, the importance of preserving stem cells during in vitro expansion and controlling cell differentiation as well as tissue organization to ensure quality and functionality of tissue-engineered organs will be discussed, while focusing on skin and cornea.
Larouche
D
D
Laboratoire d'organogénèse expérimentale, hôpital du Saint-Sacrement du CHA et département de chirurgie, université Laval, 1050, chemin Sainte-Foy, G1S 4L8, Québec, Canada.
Lavoie
A
A
Proulx
S
S
Paquet
C
C
Carrier
P
P
Beauparlant
A
A
Auger
F A
FA
Germain
L
L
D000328:Adult; D000818:Animals; D018929:Cell Culture Techniques / Q000379:methods*; D021982:Cell-Matrix Junctions; D002478:Cells, Cultured / Q000166:cytology; D003315:Cornea / Q000166:cytology; D003316:Corneal Diseases / Q000628:therapy*; D042783:Endothelial Cells / Q000166:cytology; D004847:Epithelial Cells / Q000166:cytology / Q000378:metabolism; D005109:Extracellular Matrix / Q000502:physiology*; D006801:Humans; D007231:Infant, Newborn; D015603:Keratinocytes / Q000166:cytology; D007633:Keratins / Q000502:physiology; D059630:Mesenchymal Stem Cells / Q000166:cytology* / Q000378:metabolism; D051379:Mice; D012867:Skin / Q000166:cytology / Q000254:growth & development; D012871:Skin Diseases / Q000628:therapy*; D023822:Tissue Engineering / Q000379:methods*; D014182:Transplantation, Autologous; D014738:Vibrissae / Q000166:cytology / Q000502:physiology
C118917:Krt17 protein, mouse; D007633:Keratins